View in EDS HTML Full Text PDF Full Text

Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies.

Saved in:
Bibliographic Details
Title: Effect on renal function of an iso-osmolar contrast agent in patients with monoclonal gammopathies.
Authors: Preda L (AUTHOR), Agazzi A (AUTHOR), Raimondi S (AUTHOR), Lanfranchi CF (AUTHOR), Passerini R (AUTHOR), Calvetta A (AUTHOR), Martinelli G (AUTHOR), Bellomi M (AUTHOR), Preda, Lorenzo1 (AUTHOR), Agazzi, Alberto (AUTHOR), Raimondi, Sara (AUTHOR), Lanfranchi, Carla Federica (AUTHOR), Passerini, Rita (AUTHOR), Calvetta, Albania (AUTHOR), Martinelli, Giovanni (AUTHOR), Bellomi, Massimo (AUTHOR)
Source: European Radiology. Jan2011, Vol. 21 Issue 1, p63-69. 7p.
Abstract: Objective: To assess the safety of the non-ionic iso-osmolar contrast agent iodixanol on renal function in patients with monoclonal gammopathies undergoing CT.Methods: We explored the effect of iodixanol on renal function in 30 patients with monoclonal gammopathies and 20 oncological patients with a normal electrophoretic profile (control group). The parameters used to estimate renal function were: serum creatinine, eGFR (determined 24 h before and 48 h after the administration of iodixanol), and urinary excretion of Neutrophil Gelatinase-Associated Lipocalin (NGAL) determined 2 h and 24 h after. Serum creatinine was also determined 1 month after the administration of iodixanol.Results: No significant increase in serum creatinine values were observed in the monoclonal gammopathies group and in 19/20 patients in the control group. Only 1 patient in the control group developed a transient contrast agent-induced nephropathy. We found no statistically significant difference between the two groups regarding the percentage variation from baseline values of serum creatinine, creatinine clearance, NGAL 2 h after, and eGFR. Whereas NGAL at 24 h showed a statistically significant increase in patients with Monoclonal gammopathies.Conclusion: The use of iodixanol appears to be safe in patients with monoclonal gammopathies and an eGFR≥ 60 ml/min/1.73 mq. [ABSTRACT FROM AUTHOR]
Copyright of European Radiology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Full text is not displayed to guests.
Description
Abstract:<bold>Objective: </bold>To assess the safety of the non-ionic iso-osmolar contrast agent iodixanol on renal function in patients with monoclonal gammopathies undergoing CT.<bold>Methods: </bold>We explored the effect of iodixanol on renal function in 30 patients with monoclonal gammopathies and 20 oncological patients with a normal electrophoretic profile (control group). The parameters used to estimate renal function were: serum creatinine, eGFR (determined 24 h before and 48 h after the administration of iodixanol), and urinary excretion of Neutrophil Gelatinase-Associated Lipocalin (NGAL) determined 2 h and 24 h after. Serum creatinine was also determined 1 month after the administration of iodixanol.<bold>Results: </bold>No significant increase in serum creatinine values were observed in the monoclonal gammopathies group and in 19/20 patients in the control group. Only 1 patient in the control group developed a transient contrast agent-induced nephropathy. We found no statistically significant difference between the two groups regarding the percentage variation from baseline values of serum creatinine, creatinine clearance, NGAL 2 h after, and eGFR. Whereas NGAL at 24 h showed a statistically significant increase in patients with Monoclonal gammopathies.<bold>Conclusion: </bold>The use of iodixanol appears to be safe in patients with monoclonal gammopathies and an eGFR≥ 60 ml/min/1.73 mq. [ABSTRACT FROM AUTHOR]
ISSN:09387994
DOI:10.1007/s00330-010-1908-2